phrykt

Amphastar Pharmaceuticals, Inc. (AMPH): who owns it and who trades it

As of Nov 16, 2026, AMPH insiders reported 11 open-market sales worth $2.1M and no purchases in the last 12 months, with 54% of the sale value made under pre-set 10b5-1 plans. The largest seller was William J Peters (CFO), with $1.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Amphastar Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AMPH

209 funds and institutions reported AMPH shares worth $613M at the end of Q2 2026, about 67% of the company. The largest holder is BlackRock, Inc. with 11.8%.

Funds and institutions (13F) 67%Everyone else 33%

10 largest owners, by share of the company

BlackRock, Inc.11.8%
Dimensional Fund Advisors LP5.2%
State Street Corp3.7%
Vanguard Capital Management LLC3.4%
American Century Companies Inc2.7%
Marshall Wace, LLP2.4%
Geode Capital Management, LLC2.2%
Fuller & Thaler Asset Management, Inc.2.2%
D. E. Shaw & Co., Inc.2.0%
Vanguard Portfolio Management LLC1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.22M11.85%$105M-4%
Dimensional Fund Advisors LP2.31M5.23%$46.5M+14%
State Street Corp1.64M3.72%$33.1M+2%
Vanguard Capital Management LLC1.48M3.36%$29.9M-4%
American Century Companies Inc1.18M2.67%$23.7M+16%
Marshall Wace, LLP1.07M2.42%$21.5M+4%
Geode Capital Management, LLC969,8402.20%$19.6M-1%
Fuller & Thaler Asset Management, Inc.949,2382.15%$19.2M-32%
D. E. Shaw & Co., Inc.887,0482.01%$17.9M+33%
Vanguard Portfolio Management LLC809,5681.84%$16.3M+3%
California State Teachers Retirement System729,5271.65%$36.2M+2478%
Lsv Asset Management642,0141.46%$13M-1%
Renaissance Technologies LLC525,1001.19%$10.6M-5%
Goldman Sachs Group Inc505,3601.15%$10.2M+53%
Systematic Financial Management LP437,3840.99%$8.8M-3%
Morgan Stanley434,8400.99%$8.8M+3%
UBS Group AG393,1100.89%$7.9M-6%
Hrt Financial LP387,5300.88%$7.8M+590%
Denali Advisors LLC375,9650.85%$7.6M+41%
Northern Trust Corp370,9910.84%$7.5M-0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AMPH insiders reported $0 of open-market purchases and $2.1M of sales. 54% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.1M
11 trades, 4 people
Sales under a 10b5-1 plan
54%
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 6, 2026

Purchases and sales by month

$815K$815KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026William J PetersCFOSale plan12,631$28.99$366KForm 4
Nov 4, 2026William J PetersCFOSale plan16,000$28.03$448KForm 4
Sep 21, 2026William J PetersCFOSale plan4,139$25.00$103KForm 4
Sep 16, 2026Rong ZhouVice presidentSale10,000$23.94$239KForm 4
Sep 2, 2026Rong ZhouVice presidentSale3,187$23.63$75.3KForm 4
Aug 11, 2026Richard K PrinsDirectorSale7,973$20.30$162KForm 4
Aug 7, 2026William J PetersCFOSale plan8,180$22.48$184KForm 4
Dec 17, 2025Rong ZhouVice presidentSale9,787$26.20$256KForm 4
Dec 12, 2025Floyd F. PetersenDirectorSale2,426$25.92$62.9KForm 4
Dec 11, 2025Floyd F. PetersenDirectorSale1,737$25.69$44.6KForm 4
Nov 25, 2025Richard K PrinsDirectorSale4,179$27.10$113KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
William J PetersCFO, EVP & TREASURER, Director–$1.1MNov 5, 2026
Rong ZhouSENIOR EVP, PRODUCTION CENTER–$571KSep 16, 2026
Richard K PrinsDirector–$275KAug 11, 2026
Floyd F. PetersenDirector–$108KDec 12, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AMPH short interest

Moderate short interest. 10.0% of AMPH shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.26M AMPH shares were sold short, 10.0% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 375,643 shares, buying them all back would take about 11.3 trading days (days to cover).

Shares short, % of all shares

9.99%May 15Oct 3013.3%

Days to cover

11.3May 15Oct 3017.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.26M9.99%-2%375,64311.3
Oct 15, 20264.33M10.19%-2%439,8009.8
Sep 30, 20264.41M10.36%-12%620,8327.1
Sep 15, 20264.99M11.74%-3%464,70810.8
Aug 31, 20265.13M12.07%-5%334,22215.4
Aug 14, 20265.39M12.66%+9%540,56910.0
Jul 31, 20264.93M11.59%+18%414,64611.9
Jul 15, 20264.17M9.47%+9%374,28611.2
Jun 30, 20263.85M8.72%+1%734,2345.2
Jun 15, 20263.80M8.62%+1%532,7037.1
May 29, 20263.75M8.50%-1%792,6274.7
May 15, 20263.78M8.57%+5%802,0004.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Amphastar Pharmaceuticals company events

Amphastar Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 13, 2026LeadershipThe Board of Directors of Amphastar Pharmaceuticals, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase to the authorized number of directors permitted to serve on the Board from ten (10) to eleven (11) directors and appointed… Filing
  4. Jul 8, 2026AnnouncementInternational Medication Systems, Limited, a subsidiary of the Company, received a warning letter from the FDA relating to IMS's drug manufacturing facility located in South El Monte, California. Filing
  5. Jun 3, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 16, 2026AnnouncementThe Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected to continue for an indefinite period of time. Filing
  8. Mar 6, 2026LeadershipAmphastar Pharmaceuticals, Inc., entered into executive employment agreements with each of Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, Secretary and a member of the board of directors and Rong Zhou, the Company’s Senior Executive Vice President of… Filing
  9. Mar 6, 2026AgreementAmphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar Pharmaceuticals, Inc., entered into a supply agreement with Nanjing Letop Biotechnology Co., Ltd. Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026AgreementAmphastar Pharmaceuticals, Inc, and Nanjing Hanxin Pharmaceutical Technology Co., Ltd., entered into a License Agreement pursuant to which Hanxin is granting an exclusive license to certain intellectual property controlled by Hanxin to develop, make, use and commercialize products incorporating or… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Amphastar Pharmaceuticals financials

Famous investors that hold AMPH

4 of the 50 well-known investors we track reported holding AMPH in their latest 13F filing. The largest position is Jim Simons's, worth $13.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026531,000$13.7M0.0%+1%
Ken Griffin · Citadel AdvisorsQ3 2026132,022$3.4M0.0%+713%
Paul Tudor Jones · Tudor Investment CorpQ3 202630,056$776K0.0%New
Israel Englander · Millennium ManagementQ3 20269,036$233K0.0%-72%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Amphastar Pharmaceuticals, Inc. (AMPH) stock

Who owns the most AMPH stock?

The largest reported owner of Amphastar Pharmaceuticals, Inc. (AMPH) is BlackRock, Inc., with 11.8% of the company. In total, 209 funds and institutions reported holding AMPH at the end of Q2 2026, together about 67% of the shares. See the largest owners.

Are AMPH insiders buying or selling?

In the last 12 months, AMPH insiders reported no open-market purchases and 11 sales worth $2.1M. The latest trade was on Nov 5, 2026. See every trade.

What is the short interest in AMPH?

As of Oct 30, 2026, 4.26M AMPH shares were sold short, 10.0% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 375,643 shares, buying them all back would take about 11.3 trading days (days to cover). See the history.

Which famous investors hold AMPH?

4 of the 50 well-known investors we track reported AMPH in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $13.7M. See all holders.

Executive pay

Amphastar Pharmaceuticals's chief executive was paid a total of $8.3M for the year ended Dec 31, 2025, up 7% from $7.7M the year before. In the last 12 months, Amphastar Pharmaceuticals's executives and directors bought no stock on the open market and sold $2.5M.

Chief executive, total pay$8.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.